about
Identification of polyproline II regions derived from the proline-rich nuclear receptor coactivators PNRC and PNRC2: new insights for ERα coactivator interactions.High affinity Grb2-SH3 domain ligand incorporating Cbeta-substituted prolines in a Sos-derived decapeptide.In-source fragmentation of very labile peptides in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.ERα17p, a peptide reproducing the hinge region of the estrogen receptor α associates to biological membranes: A biophysical approach.Recent advances in the development of phytoestrogens and derivatives: an update of the promising perspectives in the prevention of postmenopausal diseases.Peptides targeting estrogen receptor alpha-potential applications for breast cancer treatment.Interactions of isoflavones and other plant derived estrogens with estrogen receptors for prevention and treatment of breast cancer-considerations concerning related efficacy and safety.ERE-dependent transcription and cell proliferation: Independency of these two processes mediated by the introduction of a sulfone function into the weak estrogen estrothiazine.The sequence Pro295-Thr311 of the hinge region of oestrogen receptor α is involved in ERK1/2 activation via GPR30 in leiomyoma cells.Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.ERα17p, an ERα P295 -T311 fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements.The estrogen receptor alpha-derived peptide ERα17p (P(295)-T(311)) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERα status.Isomerization and Oligomerization of Truncated and Mutated Tau Forms by FKBP52 are Independent Processes.Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.Synthesis of 4-hydroxycoumarin and 2,4-quinolinediol derivatives and evaluation of their effects on the viability of HepG2 cells and human hepatocytes culture.Pharmacological profile of 6,12-dihydro-3-methoxy-1-benzopyrano[3,4-b] [1,4]benzothiazin-6-one, a novel human estrogen receptor agonist.Stereochemical effects during [M-H]- dissociations of epimeric 11-OH-17beta-estradiols and distant electronic effects of substituents at C(11) position on gas phase acidity.Asymmetric synthesis of 3-substituted proline chimeras bearing polar side chains of proteinogenic amino acids.Electronic effects of 11β substituted 17β-estradiol derivatives and instrumental effects on the relative gas phase acidity.A Phosphorylation-Induced Turn Defines the Alzheimer's Disease AT8 Antibody Epitope on the Tau Protein.Identification of the Tau phosphorylation pattern that drives its aggregation.Stabilisation of a short α-helical VIP fragment by side chain to side chain cyclisation: a comparison of common cyclisation motifs by circular dichroism.A β-Turn Motif in the Steroid Hormone Receptor's Ligand-Binding Domains Interacts with the Peptidyl-prolyl Isomerase (PPIase) Catalytic Site of the Immunophilin FKBP52.ERα dimerization: a key factor for the weak estrogenic activity of an ERα modulator unable to compete with estradiol in binding assays.Concentration-dependent and surface-assisted self-assembly properties of a bioactive estrogen receptor α-derived peptideBiophysical studies of the interaction between calmodulin and the R287-T311 region of human estrogen receptor α reveals an atypical binding processEstrogen receptor alpha--identification by a modeling approach of a potential polyproline II recognizing domain within the AF-2 region of the receptor that would play a role of prime importance in its mechanism of actionApplication of Circular Dichroism Spectroscopy to the Analysis of the Interaction Between the Estrogen Receptor Alpha and Coactivators: The Case of CalmodulinInteraction of the Anti-Proliferative GPER Inverse Agonist ERα17p with the Breast Cancer Cell Plasma Membrane: From Biophysics to Biology
P50
Q30009591-28761C4E-1632-4E1F-BD96-D3B1D77A2C91Q30159560-FB49FD64-9817-45B1-8539-5BC905C84CD6Q33513705-7FBA94DB-168A-4400-AEF4-785B9EEE47ABQ34199023-1F79B455-9148-4579-945D-393D8C4F6DA8Q35137574-C8A51C1C-1CD0-4256-8C8D-478D6B01E9EDQ37897608-9BA19803-2F8C-4254-BBD9-4E330FEEAFCBQ38070279-EDC87E36-44DC-4A3C-9D4D-9BCB66859887Q38654499-D2A7E360-C369-4185-9787-2BE0E89FE273Q38835213-1A61D42D-16CA-4880-9E5E-64481F08A74AQ39183133-E29EFFB0-D364-4730-B78A-6672B21C5855Q39492980-AA186EC1-089B-4603-A6A3-1F7565A0BD45Q39619285-09D13081-E83B-4F2C-8F34-4A16C49250A8Q39977984-3682B397-7499-48E9-9683-13F1E309F30BQ40175263-B160C74C-A983-47C5-96C2-7DB2DBFC1F73Q40500606-12477577-356A-4BC2-9DB1-1E268870A991Q40742488-8520D19D-E2DC-4D55-B356-22907AF4E4DDQ43264248-595C58B0-0019-4562-830A-F8B448401B0CQ45139791-4D37CB6A-27F7-4336-8AB6-78A72412D315Q45388940-1EA085DD-A207-4E1D-AB02-E7B984A1FF87Q48226579-35F9388F-640B-4B34-96B5-145CD1AF4533Q50258556-C56250AF-AC20-42F1-ACF2-78BD7D36AB6AQ50956163-D9848F83-05A8-4875-A1F5-FB5BCA373F88Q51493690-027872E5-DED9-46B1-B086-7F6401414B1FQ51649747-FF4A9563-BF3E-4BF5-BC69-E194C79D3BA8Q57554276-9257176B-170C-4FBE-BFD8-7B84E8CA63D2Q58037834-4DEDFDC4-90A4-4EB7-9471-E7B0FF1657E4Q79676952-46D4E7F3-D751-4D1D-9255-7934E33A016EQ86741529-D9B28AD7-9748-4E57-9D81-8F2B96187D55Q89783056-C31A9461-9EA6-479C-A05A-9E3DA572B061
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yves Jacquot
@ast
Yves Jacquot
@en
Yves Jacquot
@es
Yves Jacquot
@nl
Yves Jacquot
@sl
type
label
Yves Jacquot
@ast
Yves Jacquot
@en
Yves Jacquot
@es
Yves Jacquot
@nl
Yves Jacquot
@sl
prefLabel
Yves Jacquot
@ast
Yves Jacquot
@en
Yves Jacquot
@es
Yves Jacquot
@nl
Yves Jacquot
@sl
P106
P21
P31
P496
0000-0002-4046-9829